Physician profile
Robert Tymoczko
NPI 1053483362
$3,215.42
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $621 · 2021: $1,269 · 2022: $661.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,155.99 | 2019-2022 | |
| Novo Nordisk INC | $470.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $299.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.56 | 2019-2022 | |
| Lilly USA, LLC | $218.48 | 2020-2022 | |
| Abbvie INC. | $121.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.22 | 2021-2022 | |
| Glaxosmithkline, LLC. | $81.67 | 2021-2022 | |
| Amarin Pharma, INC. | $75.72 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $71.13 | 2019-2022 | |
| Pfizer INC. | $69.54 | 2021-2022 | |
| Amgen INC. | $63.37 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $41.97 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.35 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $36.91 | 2022 | |
| Allergan, INC. | $21.22 | 2020 | |
| Currax Pharmaceuticals LLC | $16.34 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.87 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.58 | 2021 | |
| Eisai INC. | $11.47 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tymoczko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.